Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Eftilagimod Alpha

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design
    Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design

    22 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/22/2916491/0/en/Immutep-Announces-Successful-Meeting-with-FDA-on-Phase-III-Design-in-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    22 Jul 2024
    Share Share
    Immutep Reports Positive Results In First Line Head And Neck Cancer
    Immutep Reports Positive Results In First Line Head And Neck Cancer

    11 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/11/2912179/0/en/Immutep-Reports-Positive-Results-in-First-Line-Head-and-Neck-Squamous-Cell-Carcinoma-Patients-with-Negative-PD-L1-Expression.html

    GLOBENEWSWIRE
    11 Jul 2024
    Share Share
    Immutep To Present Clinical Results At ESMO Virtual Plenary And Host Webcast
    Immutep To Present Clinical Results At ESMO Virtual Plenary And Host Webcast

    03 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/03/2908114/0/en/Immutep-Announces-Details-for-Oral-Presentation-at-ESMO-Virtual-Plenary-Session-and-Webcast-to-Discuss-Clinical-Results.html

    GLOBENEWSWIRE
    03 Jul 2024
    Share Share
    Commercial Manufacturing of Eftilagimod at 2000L Scale Granted Authorization
    Commercial Manufacturing of Eftilagimod at 2000L Scale Granted Authorization

    21 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/21/2747207/0/en/Commercial-Manufacturing-of-Eftilagimod-Alpha-at-2000L-Scale-Granted-Authorization-for-Clinical-Trial-Use.html

    GLOBENEWSWIRE
    21 Sep 2023
    Share Share
    TACTI-002 Data Show Antitumor Activity With Second-Line Eftilagimod Alpha
    TACTI-002 Data Show Antitumor Activity With Second-Line Eftilagimod Alpha

    01 Sep 2023

    // ONCLIVE

    https://www.onclive.com/view/tacti-002-data-show-antitumor-activity-with-second-line-eftilagimod-alpha-and-pd-1-inhibition-in-hnscc

    ONCLIVE
    01 Sep 2023
    Share Share
    Immutep Efti in Combination with Pembrolizumab Achieves Benefit in 1L NSCLC
    Immutep Efti in Combination with Pembrolizumab Achieves Benefit in 1L NSCLC

    17 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/17/2670943/0/en/Immutep-s-Efti-in-Combination-with-Pembrolizumab-Achieves-Excellent-Initial-Overall-Survival-Benefit-in-1st-Line-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    17 May 2023
    Share Share